Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–307 of 307 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease Clear all

Conditions: Nonalcoholic Steatohepatitis, Ultrasound, Elastography
Interventions: Ultrasound application; Diagnostic Test
Lead sponsor: Tokyo Medical University; Other
Eligibility: 20 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Parker, Colorado • Evanston, Illinois + 2 more

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Placebo, PF-06835919 Low Dose, PF-06835919 High Dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Los Angeles, California • DeLand, Florida • Miami, Florida + 6 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions: FT-4101, FT-4101 placebo, Deuterated Water; Drug · Other
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Chula Vista, California • Montclair, California

Conditions: Nonalcoholic Steatohepatitis
Interventions: Erchonia Verju Laser, Erchonia EVRL Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Non-alcoholic Fatty Liver Disease in Women With PCOS
Interventions: Saroglitazar Magnesium 4 mg Tablet, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 13
States / cities: Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more

Conditions: Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions: 300mg Gemcabene, 600mg Gemcabene; Drug
Lead sponsor: Elif Oral; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Pemvidutide, Placebo; Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more

Conditions: Liver Diseases
Interventions: Pioglitazone, Vitamin E, Matching placebo; Drug · Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: TERN-201, Placebo; Drug · Other
Lead sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more

Conditions: Fatty Liver
Interventions: Glucophage (Metformin), Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Placebo, ECC4703, ECC0509; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 68
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 58 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: MRI-PDFF; Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 150
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more

Conditions: Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
Interventions: Metreleptin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 5 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions: GSK4532990, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 80
States / cities: Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Not listed
Lead sponsor: Natalie Torok; Other
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: BMS-986263, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 22 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: Placebo, ARI-3037MO; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference

6-week Safety and PD Study in Adults With NAFLD

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

Study of Gemcabene in Adults With FPLD

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

Phase 2b Study of GSK4532990 in Adults With NASH

Novel MRE Technique to Assess a Risk Factor for Liver Cancer

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis